SCHEMBL1202173

SCHEMBL1202173

O=C(Nc1nc2c(C(=O)Nc3ncc[nH]3)cccc2[nH]1)c1ccnc(C#Cc2ccccc2)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 2/20 0.45
MAOB P27338 3/20 0.43
ADORA2A P29274 3/20 0.43
ADORA2B P29275 1/20 0.43
ADORA1 P30542 1/20 0.43
PARP1 P09874 4/20 0.40
NPC1 O15118 9/20 0.40
RAB9A P51151 9/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
PKM P14618 2/20 0.40
PARP2 Q9UGN5 3/20 0.38
CDK12 Q9NYV4 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CDK1 P06493 1/20 0.38
CDK2 P24941 1/20 0.38
CDK5 Q00535 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240702 0.89 MAOB (0.47) IRAK4MAOBADORA2AADORA2BADORA1
SCHEMBL1201483 0.86 IRAK4 (0.45) IRAK4MAOBADORA2AADORA2BADORA1
SCHEMBL1201956 0.86 MAOB (0.42) IRAK4MAOBADORA2AADORA2BADORA1
SCHEMBL1202093 0.86 MAOB (0.42) IRAK4MAOBADORA2AADORA2BADORA1
SCHEMBL9611644 0.84 MAOB (0.48) IRAK4MAOBADORA2AADORA2BADORA1
SCHEMBL1201618 0.83 IRAK4 (0.62) IRAK4MAOBADORA2AADORA2BADORA1
SCHEMBL1201681 0.83 MAOB (0.43) IRAK4MAOBADORA2AADORA2BADORA1
SCHEMBL1202325 0.82 MAOB (0.40) IRAK4MAOBADORA2AADORA2BADORA1
SCHEMBL1202317 0.82 IRAK4 (0.53) IRAK4MAOBADORA2AADORA2BADORA1
SCHEMBL1202120 0.81 MAOB (0.47) IRAK4MAOBADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946259-B2 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2015-02-03 US disclosed
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2014-03-06 US disclosed
US-20110065713-A1 Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2011-03-17 US disclosed
US-7893267-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2011-02-22 US disclosed
US-7893267-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2011-02-22 US disclosed
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors VTVX HOLDINGS II LLC 2009-12-31 US disclosed
WO-2006099379-A2 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS TRANSTECH PHARMA, INC. (US) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP IRAK4 4792/4885MAOB 269/4885ADORA2A 3841/4885
US-20110065713-A1 Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors BACE1, BACE2, APP IRAK4 4784/4885MAOB 127/4885ADORA2A 3347/4885
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP IRAK4 4792/4885MAOB 269/4885ADORA2A 3841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.